Twenty years after Europe licensed a testosterone treatment for women, the US Food and Drug Administration has asked for evidence on a use it has never approved. A new unreviewed study, meanwhile, raises questions about heart safety.
Ageing Well
Evidence-based reporting, analysis and perspectives on women’s health worldwide. Updated as stories develop.
US regulator fast-tracks review of non-hormonal hot flush drug for women on breast cancer therapy
Elinzanetant, a non-hormonal pill that acts on the brain’s temperature control centre, is under fast-track review in the US for hot flushes caused by breast cancer therapy. Regulators in the UK, the EU, Switzerland and Canada have already approved it for this use.
Earlier menopause linked to faster memory decline
Women who reached menopause earlier had faster declines in memory and thinking in later life, a US study of 2,603 older women suggests. Its senior author sees midlife as a window to act on risk factors, and tackling such factors could prevent or delay nearly half of dementia cases across the population.
World Osteoporosis Day: why bone health is decided long before menopause
Most women who break a bone after 50 are never assessed for osteoporosis, though treatment can cut hip fracture risk by up to 40%. Ahead of World Osteoporosis Day on 20 October, the evidence points to fracture liaison services and bone building in girlhood as the approaches that work.
Stories filed under this theme will appear here once published.